抗原负载DC-CIK细胞治疗晚期视网膜母细胞瘤的疗效及其安全性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (903 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the clinical efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells (DC) and cytokine-induced killer cells (CIK) (Ag-DC-CIK) combined with routine therapy in the treatment of advanced retinoblastoma (RB). Methods 26 patients suffering from RB who were diagnosed as advanced RB in the General Hospital of the Chinese People’s Armed Police Forces between December 2011 and December 2014. 13 patients received Ag-DC-CIK combined with routine treatment (combination group). The other patients received routine therapy (routine group). Results The combination group totally received 67 cycles (134 times) Ag-DC-CIK therapy. At the end of the follow-up, all patients in combination group who suffered D got the opportunity of reserving eyes; 2 out of 4 patients who lost the opportunity of operation had surgery eventually. All the group D patients of routine group underwent enucleation. 1 out of 4 patients who lost the opportunity of operation had surgery eventually. CD3⁺, CD4⁺ , CD4⁺/CD8⁺ and CD3⁺ CD56⁺ proportion in the combination group was higher than in another group, CD8⁺ proportion in the combination group was lower than in the routine group, and the difference was statistically significant (P<0.05). Only one patient had a fever (37.8 ℃) during the therapy, and could return to normal itself. Both groups of patients’ hepatorenal function, blood biochemistry and ECG had no statistically significant differences. Conclusions Ag-DC-CIK combined with routine therapy in the treatment of advanced RB is efficient and safe.

Key words： cytokine-induced killer cells dendritic cells retinoblastoma chemotherapy safety

Received: 02 March 2015

ZTFLH:

739.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHANG Xiaowen
	WANG Jun
	SUN Yanfeng
	MIAO Lixia
	YUAN Hailian
	LIU Hongyan
	LI Yanshan
	YANG Xinji
	ZHANG Xianglan
	LIU Qiuling

Cite this article:

CHANG Xiaowen,WANG Jun,SUN Yanfeng等. Efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells and cytokine-induced killer cells combined with routine therapy in the treatment of advanced retinoblastoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(7): 707-711.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I7/707

[1]	Zhan H L, Gao X, Pu X Y, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma [J]. Chin Med J (Engl), 2012, 125(21):3771-3777.
[2]	Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients [J]. Cancer Immunol Immunother, 2013, 62(1): 65-73.
[3]	苏毅,易海,范方毅,等.荷载自体白血病抗原的DC-CIK细胞预防急性髓细胞性白血病自体造血干细胞移植后复发的临床研究[J].中国输血杂志,2010,23(12):1024-1028.
[4]	Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification [J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53.
[5]	Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis [J]. Int Immunopharmacol, 2014, 22(2): 451-464.
[6]	Jkel C E,Hauser S,Rogenhofer S,et al.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma [J]. Clin Dev Immunol, 2012,2012: 1-7.
[7]	Wang Y F, Kunda P E, Lin J W, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells [J]. Oncol Rep, 2013, 29(5): 1841-1850.
[8]	Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis [J]. J Cancer Res Clin Oncol, 2013, 139(8): 1357-1372.
[9]	刘清池,张慧敏,张玉娜,等. DC-CIK细胞清除微小残留白血病的临床研究[J].中国肿瘤生物治疗杂志,2013,20(4): 398-403.
[10]	Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences [J]. Clin Transl Oncol, 2013, 15(10): 780-788.
[11]	张俊萍,毛光华,史天良,等.DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤生物治疗杂志,2011,18(4): 424-429.
[12]	龚奕,陈幸华,张曦,等.急性髓细胞白血病患者DC-CIK治疗后T细胞亚群动态变化的临床观察[J].2012,25(2):112-114.